Can Oral Insulin Given to Infants Prevent Type 1 Diabetes? What the POInT Trial Found

Type 1 diabetes develops when the immune system mistakenly attacks the insulin-producing cells in the pancreas. This autoimmune process often begins with the body making antibodies against insulin and other islet antigens—proteins found on these cells.

The POInT trial asked a fundamental question: what if we gave high-dose oral insulin to babies before their immune systems turned against it? Could early exposure, delivered through the gut, teach the immune system to tolerate insulin instead of attacking it?

Researchers screened newborns across seven research sites in Germany, Poland, Sweden, Belgium, and the United Kingdom. They identified infants who carried genetic markers indicating a greater than 10% risk of developing islet autoimmunity—the first step toward Type 1 diabetes.

Babies aged 4 to 7 months were randomly assigned to receive either daily oral insulin or a matching placebo. The insulin dose was gradually increased over time, starting at 7.5 mg and climbing to 22.5 mg and then 67.5 mg daily. Infants received their assigned treatment until age 3 and were then monitored until age 6.5 years.

The primary goal was to see whether participants developed two or more islet autoantibodies or progressed to diabetes during the entire follow-up period.

The trial did not meet its primary endpoint. Daily high-dose oral insulin did not reduce the overall development of islet autoantibodies compared with placebo: roughly 10% of participants in the treated group developed two or more islet autoantibodies or diabetes during follow-up, and the rate in the placebo group was not meaningfully different. As a primary prevention strategy tested this way, oral insulin did not work.

Exploratory analyses — which are hypothesis-generating rather than conclusive — pointed to some signals worth further study, including a suggestion that progression to clinical Type 1 diabetes may have been delayed in treated children, and that responses differed depending on a child's insulin gene variant. These secondary observations were not the trial's primary test and would need to be confirmed in studies designed specifically to answer them.

The POInT trial represents a major effort to test primary prevention—intervening before any signs of autoimmunity appear—in infants at highest genetic risk. By studying oral insulin delivered through the gut rather than injected, researchers explored whether the route of exposure matters for immune tolerance.

Results from studies like POInT help researchers understand the natural history of Type 1 diabetes autoimmunity and whether early interventions can alter the disease course. This knowledge guides the design of future prevention trials and helps identify which approaches show the most promise.

Origin: YouTube / Does It Change Practice? (Video report). Evidence: Video report, corroborated with 1 indexed study. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.